Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

Journal of Viral Hepatitis

Volumn 11, Issue 2, 2004, Pages 141-147

  Idilman, R ^a   Arat, M ^a   Soydan, E ^a   Toruner M ^a   Soykan, I ^a   Akbulut, H ^a   Arslan, O ^a   Ozcan M ^a   Turkyilmaz A R ^a   Bozdayi, M ^a   Karayalcin S ^a   Van Thiel, D H ^b   Ozden A ^a   Beksac M ^a   Akan, H ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hepatitis B virus; Lamivudine; Lymphoma; Malignancy; Prophylaxis

Indexed keywords

ANTINEOPLASTIC AGENT; LAMIVUDINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CHRONIC GRANULOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE; HUMAN; INFECTION PREVENTION; INTERMETHOD COMPARISON; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; VIRUS REACTIVATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; CARRIER STATE; DNA, VIRAL; FEMALE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED;

EID: 12144289779     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00479.x     Document Type: Article

References (20)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 323: 1733-1745.
2. Ustün C, Koc H, Karayalcin S et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 20: 289-296.
3. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-298.
4. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002; 97: 1618-1628.
5. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B Infection. N Engl J Med 1995; 333: 1657-1661.
6. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Haan HW, Goodman Z. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.
7. Hoofnagle JH, Dusheiko GM, Schafer DF et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-449.
8. Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81: 987-991.
9. Steinberg JL, Yeo W, Zhong S et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: precore/core mutations may play an important role. J Med Virol 2000; 60: 249-255.
10. Lim LL, Wai CT, Lee YM et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002; 16: 1939-1944.
11. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391-396.
12. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991; 100: 182-188.
13. Lau GKK, He M, Fong DYT et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoletic cell transplantation. Hepatology 2002; 36: 702-709.
14. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995; 22: 36-43.
15. Tur-Kaspa R, Burk RD, Shaul Y, Shaffritz DA. Hepatitis B virus contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986; 83: 1627-1631.
16. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
17. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398-4402.
18. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-1716.
19. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-1677.
20. Chan TM, Fang GX, Tang CSO, Cheng IKP, Lai KN, Ho SKN. Preemptive lamivudine therapy based on HBV-DNA level in HbsAg-positive kidney allograft recipients. Hepatology 2002; 36: 1246-1252.